Cryo-Cell International, Inc. (CCEL)

Market Cap	33.99M
Revenue (ttm)	29.89M
Net Income (ttm)	1.30M
Shares Out	8.52M
EPS (ttm)	0.15
PE Ratio	26.60
Forward PE	n/a
Dividend	$0.90 (22.56%)
Ex-Dividend Date	Sep 1, 2022

Volume	1,387
Open	4.02
Previous Close	4.01
Day's Range	3.99 - 4.02
52-Week Range	3.99 - 9.55
Beta	0.38
Analysts	Buy
Price Target	12.24 (+206.77%)
Earnings Date	Feb 28, 2023

About CCEL

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technolo...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Jan 21, 1997
• Employees: 83
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CCEL

Financial Performance

In 2021, CCEL's revenue was $28.88 million, a decrease of -7.26% compared to the previous year's $31.15 million. Earnings were $2.08 million, a decrease of -42.52%.

Analyst Forecast

According to 7 analysts, the average rating for CCEL stock is "Buy." The 12-month stock price forecast is $12.24, which is an increase of 206.77% from the latest price.

Price Target

$12.24

(206.77% upside)

Analyst Consensus: Buy